A case of left ventricular assist device application for chemotherapy-related cardiomyopathy caused by trastuzumab and anthracycline

AbstractLeft ventricular assist device (LVAD) is an established therapy for patients with severe heart failure. Because the incidence of cardiotoxicity owing to anticancer agents is low, it is difficult to predict the recovery prospects when the cause of heart failure is due to anticancer agents. In this context, cancer patients who present with severe symptoms of heart failure and who fail medical therapy for heart failure may pose a dilemma, especially in countries such as Japan where implantable LVADs are not approved for purposes other than bridging to transplant. Recently, we encountered a 32-year-old woman with chemotherapy-related cardiomyopathy that developed after anticancer treatment using trastuzumab and anthracycline. LVAD therapy was the only option to save the young woman. The patient received an extracorporeal LVAD, her cardiac function gradually recovered while on support, and the device was successfully removed.
Source: Journal of Artificial Organs - Category: Transplant Surgery Source Type: research

Related Links:

Limana Magenta Cancer treatment has made significant progress in the cure of different types of tumors. Nevertheless, its clinical use is limited by unwanted cardiotoxicity. Aside from the conventional chemotherapy approaches, even the most newly developed, i.e., molecularly targeted therapy and immunotherapy, exhibit a similar frequency and severity of toxicities that range from subclinical ventricular dysfunction to severe cardiomyopathy and, ultimately, congestive heart failure. Specific mechanisms leading to cardiotoxicity still remain to be elucidated. For instance, oxidative stress and DNA damage are consi...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Review Source Type: research
AbstractPurpose of ReviewCancer treatment –related cardiotoxicity (CTRC) represents a significant cause of morbidity and mortality worldwide. The purpose of our review is to summarize the epidemiology, natural history, and pathophysiology of cardiotoxicity-related to cancer treatment. We also summarize appropriate screening, surveillance, and management of CTRC. While cardiotoxicity is characteristically associated with anthracyclines, HER2-B antagonists, and radiation therapy (XRT), there is growing recognition of toxicity with immune checkpoint inhibitors (ICI), tyrosine kinase inhibitors, and proteasome inhibitors...
Source: Current Heart Failure Reports - Category: Cardiology Source Type: research
Conclusions: In anthracycline-treated cancer patients, the increase in plasma levels of NT-proBNP and of hs-cTnT can predict the development of anthracycline-induced cardiomyopathy. Early identification of at-risk patients will potentially allow for targeted dose reductions and will diminish the number of patients developing cardiac pathology.
Source: American Journal of Therapeutics - Category: Drugs & Pharmacology Tags: Original Investigations Source Type: research
CONCLUSION: Troponin I and NT-ProBNP at admission are the best predictors of re-hospitalization 6 months after discharge among patients with HFrEF. Hemoglobin is the only predictor of 30 -day rehospitalization among HFrEF patients in this study. High-risk patients may require aggressive therapy to improve outcomes. PMID: 31875779 [PubMed - in process]
Source: Cardiovascular and Hematological Agents in Medicinal Chemistry - Category: Cardiology Tags: Cardiovasc Hematol Agents Med Chem Source Type: research
German cancer registry (Robert-Koch-Institute) data has shown a 16 fold risk of cancer in those with peripartum cardiomyopathy [1]. According to the report 21 of 236 patients had cancer, of which 12 had cancer diagnosed before peripartum cardiomyopathy. 11 of them had cardiotoxic chemotherapy. Of these, 17% fully recovered cardiac function compared to 55% of peripartum cardiomyopathy patients without cancer. Of the 10 patients who developed cancer after peripartum cardiomyopathy, 80% had left ventricular ejection fraction of 50% or more after cancer therapy. Authors mention that the high prevalence could be due to geneti...
Source: Cardiophile MD - Category: Cardiology Authors: Tags: Cardio Oncology Source Type: blogs
Ninefold higher cancer occurrence seen both before and after peripartum cardiomyopathy diagnosis
Source: The Doctors Lounge - Oncology - Category: Cancer & Oncology Tags: Cardiology, Family Medicine, Gynecology, Oncology, Pathology, Journal, Source Type: news
Publication date: Available online 17 December 2019Source: Reports of Practical Oncology &RadiotherapyAuthor(s): Ivo ŠteinerAbstractThe aim of this paper is dual - to review the relevant literature on pathology of radiation induced heart disease (RIHD), and to present an illustrative case of our own. Therapeutic ionizing radiation, such as that used in the treatment of Hodgkin´s lymphoma and cancers of left breast, lungs, esophagus, and thymus, can cause cardiac damage that may take several years to manifest.The spectrum of RIHD is broad and includes [1] pericarditis and pericardial effusion; [2] endocardi...
Source: Reports of Practical Oncology and Radiotherapy - Category: Cancer & Oncology Source Type: research
WEDNESDAY, Dec. 18, 2019 -- Patients with peripartum cardiomyopathy (PPCM) are more likely to have cancer before PPCM diagnosis and more likely to develop cancer after PPCM, according to a study published in the December issue of the JACC:...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news
Publication date: Available online 26 November 2019Source: Redox BiologyAuthor(s): Balaraman KalyanaramanAbstractDoxorubicin (DOX), or Adriamycin, an anthracycline antibiotic discovered serendipitously as a chemotherapeutic drug several decades ago, is still one of the most effective drugs for treating various adult and pediatric cancers (breast cancer, Hodgkin's disease, lymphoblastic leukemia). However, one of the major side effects of the continuous use of DOX is dose-dependent, long-term, and potentially lethal cardiovascular toxicity (congestive heart failure and cardiomyopathy) in cancer survivors many years after ce...
Source: Redox Biology - Category: Biology Source Type: research
This study demonstrates for the first time that senescent cells secrete functional LTs, significantly contributing to the LTs pool known to cause or exacerbate idiopathic pulmonary fibrosis. Against Senolytics https://www.fightaging.org/archives/2019/11/against-senolytics/ There is no consensus in science that is so strong as to have no heretics. So here we have an interview with a naysayer on the matter of senolytic treatments, who argues that the loss of senescent cells in aged tissues will cause more harm to long-term health than the damage they will do by remaining. To be clear, I think this to be a ...
Source: Fight Aging! - Category: Research Authors: Tags: Newsletters Source Type: blogs
More News: Cancer | Cancer & Oncology | Cardiology | Cardiomyopathy | Chemotherapy | Heart | Heart Failure | Heart Transplant | Herceptin | Japan Health | Transplant Surgery | Transplants